Literature DB >> 27346624

Three-day regimen of oseltamivir for postexposure prophylaxis of influenza in wards.

N Ishiguro1, R Oyamada2, Y Nasuhara3, T Yamada4, T Miyamoto4, S Imai4, K Akizawa5, T Fukumoto5, S Iwasaki5, H Iijima6, K Ono6.   

Abstract

Inpatients who had been in close contact with patients with influenza were given oseltamivir [75mg capsules once daily for adults or 2mg/kg (maximum of 75mg) once daily for children] for three days as postexposure prophylaxis (PEP). The index patients with influenza were prescribed a neuraminidase inhibitor and were discharged immediately or transferred to isolation rooms. The protective efficacy of oseltamivir for three days was 93% overall [95% confidence interval (CI) 53-99%; P=0.023] and 94% for influenza A (95% CI 61-99%; P=0.017), which is comparable to that of seven- to 10-day regimens of oseltamivir as PEP.
Copyright © 2016 The Healthcare Infection Society. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Influenza; Oseltamivir; Postexposure prophylaxis

Mesh:

Substances:

Year:  2016        PMID: 27346624     DOI: 10.1016/j.jhin.2016.05.012

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  4 in total

1.  Five-Day vs 10-Day Postexposure Chemoprophylaxis With Oseltamivir to Prevent Hospital Transmission of Influenza: A Noninferiority Randomized Open-Label Study.

Authors:  Lidija Lepen; Rok Blagus; Maša Velušček; Rajko Saletinger; Miroslav Petrovec; Fajko F Bajrović; Daša Stupica
Journal:  Open Forum Infect Dis       Date:  2020-06-19       Impact factor: 3.835

2.  The AndroCoV Clinical Scoring for COVID-19 Diagnosis: A Prompt, Feasible, Costless, and Highly Sensitive Diagnostic Tool for COVID-19 Based on a 1757-Patient Cohort.

Authors:  Flavio A Cadegiani; Ricardo A Zimerman; Bruno Campello de Souza; John McCoy; Rute Alves Pereira E Costa; Carlos Gustavo Wambier; Andy Goren
Journal:  Cureus       Date:  2021-01-07

3.  Three-day regimen of oseltamivir for post-exposure prophylaxis of influenza in hospital wards: a study protocol for a prospective, multi-center, single-arm trial.

Authors:  Nobuhisa Ishiguro; Yoichi M Ito; Sumio Iwasaki; Miki Nagao; Hideki Kawamura; Shinichiro Kanai; Yoko Nukui; Koichi Tokuda; Takayuki Miyara; Hidetoshi Igari; Koichi Yamada; Hiroki Chikumi; Chiaki Sano; Ryuji Koike; Tetsuya Yagi; Nobuo Murakami
Journal:  BMC Infect Dis       Date:  2021-08-30       Impact factor: 3.090

4.  Clinical impact of nosocomial infection with pandemic influenza A (H1N1) 2009 in a respiratory ward in Guangzhou.

Authors:  Yangqing Zhan; Xiaojuan Chen; Weijie Guan; Wenda Guan; Chunguang Yang; Sihua Pan; Sook-San Wong; Rongchang Chen; Feng Ye
Journal:  J Thorac Dis       Date:  2021-10       Impact factor: 2.895

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.